Q4 2024 Mediwound Ltd Earnings Call Transcript
Key Points
- MediWound Ltd (MDWD) reported strong execution and significant progress in clinical development, commercial expansion, and strategic partnerships in 2024.
- EscharEx demonstrated superiority over existing products in key clinical endpoints, with a peak sales potential estimated at $725 million.
- The company secured EUR16.5 million in funding from the European Innovation Council to accelerate EscharEx development for diabetic foot ulcers.
- NexoBrid achieved significant commercial reach, generating $20.2 million in revenue, with projected growth to $24 million in 2025.
- MediWound Ltd (MDWD) strengthened its balance sheet with a $25 million PIPE financing round, providing resources for clinical and commercial growth plans.
- The company reported an operating loss of $19.4 million for the year, an increase from $15.3 million in 2023.
- Net loss for the year was $30.2 million, significantly higher than the $6.7 million loss in the prior year.
- R&D expenses increased to $8.9 million, primarily due to costs related to the EscharEx Phase 3 trial.
- SG&A expenses rose to $13.1 million, reflecting higher share-based compensation costs.
- The company's gross profit margin declined to 13% from 19.1% in the previous year, due to changes in revenue mix and higher fixed costs.
Good day, and welcome to MediWound's sports quarter and full year 2024 earnings conference call (Operator Instructions) Please note today's event is being recorded.
I would now like to turn the conference over to Dan Ferry, LifeSci Advisors. Please go ahead.
Thank you, operator, and welcome everyone. Earlier today, pre-market opened. MediWound issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2024. You may access this press release on the company's website under the investors tab. I would ask you to review the full text of our forward-looking statements within this morning's press release. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound's statements as defined under the Private Securities Litigation Reform Act of 1,995.
These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
